Curis Inc investor relations material

Curis, Inc. is a biotechnology company focused on the discovery and development of drug candidates for the treatment of human cancers. The company's clinical stage drug candidate includes Emavusertib, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphoma, acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumor cancers and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate.